Status:

ACTIVE_NOT_RECRUITING

Liver Glycogen and Hypoglycemia in Humans

Lead Sponsor:

Jason Winnick

Conditions:

Hypoglycemia; Iatrogenic

Eligibility:

All Genders

21-40 years

Phase:

PHASE1

Brief Summary

The purpose of this research study is to learn more about how sugar levels in the liver affect the ability of people both with and without type 1 diabetes. People with type 1 diabetes do not make thei...

Detailed Description

There is universal agreement that iatrogenic hypoglycemia is the single most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes (T1D). The typical patien...

Eligibility Criteria

Inclusion

  • Males and females of any race or ethnicity.
  • Aged 21-40 years.
  • Non-obese (BMI \<28 kg/m2).

Exclusion

  • Pregnant women.
  • Cigarette smoking.
  • Taking inflammation-targeting steroids (e.g., prednisone).
  • Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
  • Abnormal hematocrit or electrolyte levels.
  • The presence of cardiovascular or peripheral vascular disease.
  • The presence of neuropathy, retinopathy or nephropathy.
  • Any metal in the body that would make magnetic resonance spectroscopy dangerous.

Key Trial Info

Start Date :

August 2 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 31 2028

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT03241706

Start Date

August 2 2018

End Date

May 31 2028

Last Update

July 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Cincinnati

Cincinnati, Ohio, United States, 45267